NIH stops Viread arm in HIV prevention trial

NIH said it discontinued the oral Viread tenofovir arm in the Phase IIb VOICE (MTN-003) trial to prevent HIV after an interim futility analysis showed Viread would not meet the primary endpoint of improving the rate of new HIV infection vs. placebo. The remaining arms -- oral Truvada tenofovir/emtricitabine, 1% tenofovir vaginal gel and placebo -- will continue. The open-label trial enrolled 5,029 HIV-naive women. NIH added that there were no safety concerns with any of the products in the trial. Data from the trial are expected mid- to late-2012. ...